amg 193
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 15, 2021 (NCT05094336)
Timeline
Indications
Mechanism of action
PRMT5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06593522 | Phase 2 | Dec 18, 2024 | Amgen |
| NCT06333951 | Phase 1 | Sep 17, 2024 | Amgen |
| NCT06360354 | Phase 1 | May 29, 2024 | Amgen |
| NCT05975073 | Phase 1/Phase 2 (Phase 2) | Jul 27, 2023 | Amgen |
| NCT05094336 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2021 | Amgen |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 5 | 5 | 2 | 2021 |
1 organizations
Page 1 / 1